BCM
ABBV icon

BlueCrest Capital Management’s AbbVie ABBV Stock Holding History

BlueCrest Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-26,700
Closed -$4.86M – 116
2024
Q1 		$4.86M Sell
26,700
-39,300
-60% -$6.77M 0.24% 67
2023
Q4 		$10.2M Buy
66,000
+26,700
+68% +$3.89M 0.39% 53
2023
Q3 		$5.86M Buy
+39,300
New +$5.77M 0.26% 68
2018
Q4 		– Sell
-25,000
Closed -$2.37M – 819
2018
Q3 		$2.37M Buy
+25,000
New +$2.37M 0.06% 224

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

BlueCrest Capital Management's ABBV Position: Q1 2024 in Review

BlueCrest Capital Management sold out of AbbVie (ABBV) in Q1 2024, closing a stake of 10,400 shares — an estimated $1.79M sold.

BlueCrest Capital Management first reported a position in ABBV in Q2 2015 and held it in 14 quarters. The position peaked at $5.84M in Q2 2018. 3,379 funds tracked by Wall St. Rank hold ABBV as of Q1 2024.

  • BlueCrest Capital Management reported no remaining AbbVie position as of Q1 2024 after selling out during the quarter.
  • BlueCrest Capital Management sold 10,400 AbbVie shares in Q1 2024, an estimated $1.79M.
  • BlueCrest Capital Management first reported a position in AbbVie in Q2 2015 and held it in 14 quarters.
  • BlueCrest Capital Management's AbbVie position peaked at $5.84M in Q2 2018.
  • 3,379 funds tracked by Wall St. Rank held AbbVie as of Q1 2024.

Based on BlueCrest Capital Management's 13F filing for Q1 2024, filed 15 May 2024.